We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App




New Urinary Antigen Immunodiagnostic Assay Enables High-Throughput Qualitative Detection of Legionnaires' Disease

By LabMedica International staff writers
Posted on 18 Jul 2023

Legionnaires' Disease (LD), a severe form of atypical Community Acquired Pneumonia (CAP), is primarily caused by the Legionella species in patients needing hospitalization. More...

L. pneumophila sg 1 is responsible for 50 to 80% of LD cases globally. Sg 4 and 6, along with L. longbeachae, L. micdadei, and L. bozemanii, contribute to the majority of the remaining non-L.pneumophila sg 1 LD cases. If misdiagnosed or left untreated, LD can quickly deteriorate, leading to increased mortality rates. The death rate from LD can reach 40-80% in untreated immuno-compromised patients, but can be reduced to 5-30% with accurate identification and proper case management. Now, a new assay improves the diagnosis of atypical pneumonia by providing precise identification of the LD.

DiaSorin (Saluggia, Italy) has introduced the novel LIAISON Legionella Urinary Antigen Immunodiagnostic Assay, approved in all countries recognizing the CE Mark, as a tool for diagnosing LD. The assay, which is conducted on the LIAISON CLIA analyzers, offers a highly automated solution for microbiology laboratories. Using a simple test procedure, LD can be identified in a mere 35 minutes, enabling prompt and focused antimicrobial treatment. The LIAISON Legionella Urinary Ag assay, with its innovative "dual-antigen" design, can detect two Legionella's antigens (LPS and PAL), enhancing its sensitivity and specificity. This empowers healthcare practitioners to accurately identify antigens of Legionella pneumophila and Legionella longbeachae.

"The launch of this new assay confirms our ability to position DiaSorin as a specialty player, able to provide innovative solutions with a high medical value," said Chen Even, Chief Commercial Officer of DiaSorin. "We are confident that our new assay will strongly contribute in discriminating etiological factors in severe atypical pneumonia."

Related Links:
DiaSorin 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.